Why Are People Turning to Compounded GLP-1 Medications Right Now?

The Shortage That Started Everything

Demand for GLP-1 receptor agonists exploded after the FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021. Eli Lilly's tirzepatide (Zepbound) followed in November 2023. Manufacturers could not keep pace. The FDA placed semaglutide injection on its official drug shortage list, and that single administrative designation changed the legal field for compounding pharmacies nationwide.

What the FDA Shortage List Actually Does

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies are permitted to prepare copies of commercially available drugs when those drugs appear on the FDA shortage list. The shortage designation is not symbolic. It is the legal trigger that allowed thousands of compounding pharmacies to prepare and ship semaglutide and tirzepatide formulations directly to patients.

The FDA's official shortage database confirmed semaglutide's shortage status continuously from 2022 into early 2025. See the FDA's shortage database for current status by active ingredient.

The February 2025 Turning Point

In February 2025, the FDA declared the semaglutide shortage resolved. That declaration set a compliance clock ticking. The agency gave 503A pharmacies (those compounding for individual prescriptions) until April 22, 2025, to stop producing compounded semaglutide, and gave 503B outsourcing facilities until May 22, 2025. Tirzepatide's shortage was declared resolved earlier, in December 2024, with similar wind-down timelines.

Patients who started compounded therapy before those deadlines may still be mid-course. Many are now weighing whether to transition to branded products, seek manufacturer savings programs, or discontinue treatment entirely.

The Cost Problem Has Not Gone Away

Even with shortages easing, price remains the dominant reason patients seek compounded alternatives. Wegovy's list price sits at approximately $1,349 per month as of early 2025. Zepbound lists at approximately $1,060 per month. According to GoodRx data published alongside FDA filings, fewer than 25% of commercially insured Americans have a pharmacy benefit plan that covers anti-obesity medications without prior authorization.

What Medicare and Medicaid Cover

Medicare Part D historically excluded weight-loss drugs under the Consolidated Appropriations Act of 2021. The Treat and Reduce Obesity Act has been introduced repeatedly in Congress but has not passed as of this writing. Medicaid coverage varies by state. That leaves a large segment of the population, particularly adults aged 65 and older, without any public insurance coverage for branded GLP-1 agents used specifically for weight management.

Patients who have a qualifying diagnosis of type 2 diabetes may access semaglutide as Ozempic or tirzepatide as Mounjaro under different coverage rules, since those indications have broader formulary placement.

Manufacturer Savings Programs

Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both operate savings card programs that can reduce out-of-pocket cost to as low as $25 per month for commercially insured patients. Uninsured patients generally do not qualify for savings card pricing. That gap is where compounded medications entered for many patients: a compounded semaglutide injection from a licensed 503B facility often ran $200 to $400 per month, a fraction of the list price.

How Compounding Pharmacies Operate

Not all compounding pharmacies are equivalent. The regulatory framework creates two distinct categories.

503A Pharmacies: Patient-Specific Compounding

A 503A pharmacy prepares medications in response to a valid individual prescription. The pharmacist compounds a specific dose for a specific patient. These pharmacies are regulated primarily by state boards of pharmacy and must comply with USP standards. They may not produce large batches for general sale.

503B Outsourcing Facilities: Batch Production

A 503B outsourcing facility may produce larger batches of compounded drugs without individual prescriptions, selling to healthcare practitioners and clinics. They are registered with the FDA and subject to current good manufacturing practice (cGMP) inspections. Several telehealth platforms partnered with 503B facilities to ship compounded semaglutide or tirzepatide directly to patients at scale.

The FDA has inspected a number of 503B facilities and issued warning letters for quality control failures, including particulate contamination and improper beyond-use dating. Patients should verify that any compounding pharmacy holds an active 503B registration by checking the FDA's outsourcing facility list.

What "Compounded Semaglutide" Actually Contains

This is where patient understanding breaks down most frequently. Compounded semaglutide is not identical to Ozempic or Wegovy. The active pharmaceutical ingredient (API) used in compounded preparations is sourced from third-party bulk chemical suppliers, not from Novo Nordisk's manufacturing process.

The Semaglutide Salt Controversy

The FDA issued a specific safety communication warning that some compounders were using semaglutide sodium or semaglutide acetate (salt forms) rather than the base form of semaglutide used in FDA-approved products. The agency stated directly: "FDA is not aware of any basis for concluding that semaglutide sodium and semaglutide acetate are safe or effective." That communication appeared on the FDA's drug compounding page in 2024 and remains active.

Patients should ask their prescribing provider or compounding pharmacy to confirm which chemical form of the API is present and to provide a certificate of analysis from the API supplier.

Added Ingredients

Compounded formulations sometimes include adjunct ingredients not present in branded products, such as vitamin B12, L-carnitine, or NAD+. None of these additions have been evaluated in randomized controlled trials in combination with semaglutide. A provider recommending these blends should be able to explain the clinical rationale and the evidence (or absence of evidence) for each additive.

The Clinical Evidence Behind GLP-1 Receptor Agonists

The drive toward any GLP-1 therapy, compounded or branded, is anchored in some of the most compelling weight-management trial data published in the last decade.

STEP-1: Semaglutide 2.4 mg

The STEP-1 trial (N=1,961) compared subcutaneous semaglutide 2.4 mg weekly against placebo in adults with obesity or overweight with at least one comorbidity. At 68 weeks, the semaglutide group achieved 14.9% mean weight loss versus 2.4% in the placebo group (P<0.001). Wilding JPH et al., NEJM 2021. Body weight reductions of 5% or more were seen in 86.4% of semaglutide participants.

SURMOUNT-1: Tirzepatide 5 mg, 10 mg, 15 mg

The SURMOUNT-1 trial (N=2,539) tested tirzepatide at three doses against placebo in adults with obesity. The 15 mg dose produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001). Jastreboff AM et al., NEJM 2022. At that magnitude of weight loss, tirzepatide moved into territory previously associated only with bariatric surgery.

SELECT: Cardiovascular Outcomes with Semaglutide

The SELECT trial (N=17,604) examined semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity but without diabetes. Semaglutide reduced major adverse cardiovascular events (MACE) by 20% compared with placebo over a mean follow-up of 33.3 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). Lincoff AM et al., NEJM 2023. That cardiovascular benefit is tied to the specific semaglutide formulation tested, not to any compounded analog.

Who Is Turning to Compounded GLP-1s, and Why

The population seeking compounded GLP-1 medications is not monolithic. Based on prescribing patterns reported by telehealth platforms and pharmacy benefit managers, at least four distinct patient groups have driven demand.

Group 1: The Uninsured or Underinsured Patient

Adults without pharmacy coverage or with high-deductible plans face the full list price for branded GLP-1 agents. At $1,349 per month for Wegovy, a 12-month course costs more than $16,000. Compounded semaglutide at $200 to $400 monthly cut that figure by 70% to 85%.

Group 2: The Medicare Beneficiary

Because Medicare Part D does not cover weight-management GLP-1 drugs, beneficiaries who do not have a concurrent type 2 diabetes diagnosis have no public coverage pathway. This group has shown particularly strong uptake of compounded options through telehealth channels.

Group 3: The Patient Who Could Not Get a Prescription Locally

Primary care provider availability is uneven across the United States. Rural patients, or those whose primary care clinicians are uncomfortable with GLP-1 prescribing, have turned to telehealth platforms that offer expedited clinical assessment and compounded medication in the same workflow.

Group 4: The Dose-Titration Patient

Some patients on branded GLP-1 therapy found specific doses unavailable during shortage periods. A patient stabilized on semaglutide 1.0 mg weekly who could not fill that specific pen dose might bridge with a compounded formulation from a 503B facility. Clinicians sometimes authorized these bridges, though the pharmacokinetic equivalence was not guaranteed.

Risks Patients and Providers Should Understand

The risks of compounded GLP-1 medications are not hypothetical. The FDA has documented specific safety events.

Manufacturing Quality

The FDA's inspection of 503B facilities has uncovered issues including subpotent or superpotent preparations, meaning actual delivered doses differ from labeled doses. A superpotent preparation could expose a patient to nausea, vomiting, and gastroparesis risk at a dose above what the clinical trials established as safe. FDA's compounding page lists current warning letters and enforcement actions.

Dosing Errors from Vial-and-Syringe Administration

Branded semaglutide comes in a prefilled autoinjector pen. Most compounded formulations come as multi-dose vials requiring the patient to draw up and self-inject with a separate syringe. A 10-fold dosing error (drawing 1.0 mL instead of 0.1 mL) is technically possible and has been reported to MedWatch. The Endocrine Society's 2023 clinical guidance on obesity pharmacotherapy noted that patient education on self-injection technique is essential when vial-based formulations are used. Endocrine Society Clinical Practice Guideline.

Lack of Post-Marketing Surveillance Data

Branded products accumulate pharmacovigilance data through the FDA's FAERS system and through mandatory post-marketing studies. Compounded formulations do not. Adverse events attributed to compounded GLP-1 products may be underreported or incorrectly attributed to the branded drug class.

What the Regulatory Shift Means for Current Patients

With the FDA declaring semaglutide and tirzepatide shortages resolved in early 2025, the legal basis for compounding most GLP-1 medications has narrowed significantly.

The Wind-Down Period

503A pharmacies filling individual prescriptions faced an April 22, 2025, compliance deadline. 503B outsourcing facilities faced a May 22, 2025, deadline. After those dates, continuing to compound commercially available semaglutide formulations is an enforcement risk for pharmacies, absent a patient-specific need that branded products cannot meet (for example, a documented allergy to an excipient present in the branded formulation).

What Patients Should Do Now

Patients currently on compounded semaglutide or tirzepatide should speak with their prescribing provider before the compliance deadlines pass. Options include transitioning to a branded product with manufacturer savings card assistance, applying for patient assistance programs through Novo Nordisk or Eli Lilly, exploring whether a qualifying diagnosis (type 2 diabetes, cardiovascular disease) enables broader insurance coverage, or pausing therapy with a structured discontinuation plan to minimize rebound weight gain, which the STEP-1 extension study documented as 11.6% regain at 120 weeks post-discontinuation Wilding JPH et al., Diabetes Obes Metab 2022.

A Note on "Personalized Doses" as a Workaround

Some compounders have attempted to argue that they are producing "personalized" formulations with added ingredients, which might qualify as distinct preparations not subject to the shortage-resolution restrictions. The FDA addressed this directly in a March 2025 guidance update, stating that adding a non-active ingredient does not make a compounded drug a distinct preparation from the approved drug. Patients considering this route should understand the legal uncertainty.

Calibrate, Ro, Hims and Hers, and the Telehealth GLP-1 Market

Telehealth platforms were central to the compounded GLP-1 boom. Calibrate, one of the larger weight-management telehealth programs, offered semaglutide prescriptions paired with behavioral coaching. Ro (Ro Body), Hims and Hers, and several smaller platforms followed the same model.

These programs typically charged a monthly membership fee in addition to the medication cost. Calibrate's model involved a one-year program commitment. The convenience factor was real: patients could complete an intake, upload labs, and receive a prescription within days, without an in-person visit.

The regulatory wind-down has forced these platforms to pivot. Some have negotiated direct relationships with branded-drug manufacturers or pivoted to oral formulations. Oral semaglutide (Rybelsus, 3 mg to 14 mg daily) is FDA-approved for type 2 diabetes and remains available, though it produces more modest weight loss than the 2.4 mg injectable formulation.

Frequently Asked Questions